Literature DB >> 3989236

Prolactin and thyrotropin response to blockade of dopamine synthesis by monoiodotyrosine in subjects with postpartum and pathological hyperprolactinemia.

E Ghigo, E Ciccarelli, A Novelli, M Massobrio, E E Müller, F Camanni.   

Abstract

To better understand the state of dopamine (DA) neurotransmission in the tuberoinfundibular DA system (TIDA), monoiodotyrosine (3-iodo-L-tyrosine, MIT), a potent inhibitor of DA synthesis, was acutely administered to 8 normal women, 7 postpartum women, 8 women with pathological hyperprolactinemia and 5 women after successful removal of a prolactinoma. The effects on plasma prolactin (PRL) and thyrotropin (TSH) were compared to those induced in the same subjects by the DA receptor antagonist domperidone (DOM). MIT (1 gpo) and DOM (10 mg iv) induced qualitatively similar hormonal responses, although the PRL- and TSH-releasing effects of DOM were always greater than those of MIT. In control subjects, MIT treatment induced a consistent rise in plasma PRL (peak increment 45.2 +/- 13 ng/ml at 120 min); in the same subjects DOM induced a prompter and higher PRL response, (peak increment 147.8 +/- 26 ng/ml at 30 min). MIT failed to alter plasma TSH levels, while DOM induced a significant rise in plasma TSH. In postpartum women MIT induced a prompter and higher PRL rise than that occurring in controls (peak increment 180.3 +/- 20 ng/ml at 90 min), though also in this instance DOM proved to be a more potent PRL releaser (peak increment 345.7 +/- 88 ng/ml at 30 min) than MIT. MIT was unable to stimulate TSH secretion, while DOM induced a significant rise in plasma TSH. In women with pathological hyperprolactinemia MIT failed to alter baseline PRL levels while DOM slightly increased them (peak increment 14.7 +/- 3 ng/ml at 30 min).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3989236     DOI: 10.1007/BF03350635

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  21 in total

1.  The metabolism of iodotyrosines. I. The fate of mono- and di-iodotyrosine in normal subjects and in patients with various diseases.

Authors:  J B STANBURY; A A KASSENAAR; J W MEIJER
Journal:  J Clin Endocrinol Metab       Date:  1956-06       Impact factor: 5.958

2.  Biochemical and pharmacological effects of iodo-tyrosines; relation to tyrosine hydroxylase inhibition in vivo.

Authors:  S Spector; R O Mata; A Sjoerdsma; S Udenfriend
Journal:  Life Sci       Date:  1965-07       Impact factor: 5.037

3.  Biochemical indices of tuberoinfundibular dopaminergic neuronal activity during lactation: a lack of response to prolactin.

Authors:  K T Demarest; D W McKay; G D Riegle; K E Moore
Journal:  Neuroendocrinology       Date:  1983-02       Impact factor: 4.914

4.  Prolactin response to dopamine synthesis inhibition using monoiodotyrosine in subjects on oral contraceptives and patients with pathological hyperprolactinemia.

Authors:  K Y Ho; G A Smythe; L Lazarus
Journal:  J Clin Endocrinol Metab       Date:  1983-04       Impact factor: 5.958

5.  Rapid induction of prolactin secretion by 3-iodo-L-tyrosine.

Authors:  G A Smythe; J F Brandstater; L Lazarus
Journal:  Neuroendocrinology       Date:  1974       Impact factor: 4.914

6.  Prolactin-releasing effect of a novel anti-dopaminergic drug, domperidone, in the rat.

Authors:  D Cocchi; I Gil-Ad; M Parenti; E Stefanini; V Locatelli; E E Müller
Journal:  Neuroendocrinology       Date:  1980       Impact factor: 4.914

7.  Abnormal prolactin responsivity to dopaminergic suppression in hyperprolactinemic patients.

Authors:  S Bansal; L A Lee; P D Woolf
Journal:  Am J Med       Date:  1981-12       Impact factor: 4.965

8.  Stimulation of prolactin secretion by neuroleptics in rats with medial basal hypothalamic lesions.

Authors:  C Y Cheung; A C Neill; R I Weiner
Journal:  Neuroendocrinology       Date:  1981-06       Impact factor: 4.914

9.  Domperidone, a novel and safe gastrokinetic anti-nauseant for the treatment of dyspepsia and vomiting.

Authors:  A J Reyntjens; C J Niemegeers; J M Van Nueten; P Laduron; J Heykants; K H Schellekens; R Marsboom; A Jageneau; A Broekaert; P A Janssen
Journal:  Arzneimittelforschung       Date:  1978

10.  Altered dopaminergic regulation of thyrotrophin release in patients with prolactinomas: comparison with other tests of hypothalamic-pituitary function.

Authors:  M F Scanlon; M D Rodriguez-Arnao; A M McGregor; D Weightman; M Lewis; D B Cook; A Gomez-Pan; R Hall
Journal:  Clin Endocrinol (Oxf)       Date:  1981-02       Impact factor: 3.478

View more
  1 in total

Review 1.  Hyperprolactinemia: neuroendocrine and diagnostic aspects.

Authors:  F Camanni; E Ciccarelli; E Ghigo; E E Müller
Journal:  J Endocrinol Invest       Date:  1989-10       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.